Agnès Quemener

This inventor holds 8 USPTO granted patents and 5 EPO patents. Top assignees: National Institute of Health and Medical Research, The University of Nantes, Centre National De La Recherche Scientifique. Active years: 2010-2025.

USPTO Granted Patents = 8

% Patents Active = 50.0

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 4.8

ph-index = 4

Forward Citations = 89(Granted Patents)

Company Filing History:

7 out of 1,853

National Institute of Health and Medical Research

patents

4 out of 156

The University of Nantes

patents

3 out of 5,383

Centre National De La Recherche Scientifique

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12466866 - MUTATED INTERLEUKIN-34 (IL-34) POLYPEPTIDES AND USES THEREOF IN THERAPY (2025-11-11),

2. 12134639 - IL-15Rα sushi domain—IL-15 fusion proteins (2024-11-05),

3. 11795144 - Inhibitors of RAC1 and uses thereof for treating cancers (2023-10-24),

4. 11008374 - Uses of IL-15 antagonists for the treatment of autoimmune and inflammatory diseases (2021-05-18),

5. 10358477 - IL-15Ralpha sushi domain—IL-15 fusion proteins (2019-07-23),

6. 10202433 - IL-15 mutant polypeptides as IL-15 antagonists and encoding nucleic acids (2019-02-12),

7. 9493533 - IL-15 mutants having antagonist activity (2016-11-15),

8. 7858081 - IL-15 mutants having agonists/antagonists activity (2010-12-28),

Title: Agnès Quemener: Innovator in Therapeutic Polypeptides

Introduction

Agnès Quemener is a notable inventor based in Nantes, France. She has made significant contributions to the field of therapeutic polypeptides, particularly through her innovative research and development efforts.

Latest Patents

Agnès holds a patent for "Mutated Interleukin-34 (IL-34) Polypeptides and Uses Thereof in Therapy." This patent represents her pioneering work in the therapeutic applications of IL-34, showcasing her commitment to advancing medical science.

Career Highlights

Agnès is affiliated with the University of Nantes, where she continues to engage in groundbreaking research. Her work has not only contributed to her field but has also positioned her as a key figure in the academic community.

Collaborations

Agnès collaborates with esteemed colleagues, including Carole Guillonneau and Ignacio Anegon. These partnerships enhance her research and expand the impact of her innovations.

Conclusion

Agnès Quemener exemplifies the spirit of innovation in the realm of therapeutic polypeptides. Her contributions are paving the way for future advancements in medical therapies.